Core Insights - Connect Biopharma announced positive topline data from its Phase 1 study of IV rademikibart in patients with asthma or COPD, demonstrating rapid improvement in forced expiratory volume in one second (FEV1) [5][2] - The company entered into a securities purchase agreement for $20.2 million equity financing, extending its cash runway into the second half of 2027 [6][2] Development Highlights - Rademikibart's Phase 2 Seabreeze STAT studies for acute asthma and COPD were initiated in 2025, with topline data expected mid-2026 [2][4] - The Phase 3 study results for rademikibart in moderate-to-severe atopic dermatitis (AD) showed rapid and durable efficacy, with ~90% of patients achieving near-maximal responses [4][5] Financial Overview - As of December 31, 2025, the company reported cash, cash equivalents, and short-term investments of $44.3 million, which is expected to fund operations into the second half of 2027 [9][20] - For the three months ended December 31, 2025, the net loss was $15.1 million, or ($0.27) per share, compared to a net loss of $8.9 million, or ($0.16) per share for the same period in 2024 [9][18] Corporate Developments - The company has entered into a private placement agreement to sell 6,130,000 shares at $3.25 per share, with gross proceeds expected to be $20.2 million [6][2] - Connect Biopharma has granted an exclusive license to Simcere Pharmaceutical Co., Ltd. for rademikibart in Greater China, with potential milestone payments up to approximately $110 million [11][9]

Core Viewpoint - Connect Biopharma Holdings Limited has secured funding through a private placement, extending its cash runway into the second half of 2027, which will support its clinical-stage product development and operational needs [1][4]. Group 1: Funding Details - The company has entered into a securities purchase agreement to sell 6,130,000 shares at a price of $3.25 per share, anticipating gross proceeds of approximately $20.2 million before expenses [1][2]. - The private placement is expected to close around March 31, 2026, subject to customary closing conditions, and was led by Panacea Venture along with participation from other healthcare-focused investors [2][3]. Group 2: Use of Proceeds - The net proceeds from the financing will be utilized for research and development of clinical-stage product candidates, working capital, and other general corporate purposes [4]. Group 3: Company Overview - Connect Biopharma is focused on transforming care for asthma and COPD, advancing its product rademikibart, which targets IL-4Rα and is currently in global clinical studies [7]. - The company has an exclusive licensing agreement with Simcere Pharmaceutical Co., Ltd. for rademikibart in Greater China, with potential milestone payments of up to approximately $110 million and tiered royalties on net sales [7].

Core Insights - Connect Biopharma reported positive topline preliminary results for its Phase 1 clinical pharmacology study of intravenous (IV) rademikibart, indicating rapid improvement in lung function for asthma and COPD patients [1][2] Group 1: Clinical Study Results - Rademikibart administered as a single 300 mg 2-minute IV push produced rapid improvement in FEV1, with many patients experiencing improvements of ≥200 mL as early as 15 minutes post-dosing [1] - Mean FEV1 improvements of approximately 200 - 400 mL were maintained through Day 29 in asthma and COPD patients [1][4] - The study demonstrated that rademikibart has a unique beneficial effect on bronchodilation, independent of blocking IL-4Rα [2][5] Group 2: Study Design and Patient Demographics - The Phase 1 study was a single-dose, placebo-controlled trial evaluating IV rademikibart in healthy volunteers and patients with stable asthma and COPD [2] - In the patient cohort, the mean baseline FEV1 was 1.9 L for asthma patients and 1.55 L for COPD patients, with a majority being current smokers [2] Group 3: Future Developments - Recruitment is ongoing for Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD, with topline data expected in mid-2026 [1][5] - The company plans to engage with the U.S. Food and Drug Administration (FDA) to align on a Phase 3 program following the Phase 2 studies [5] Group 4: Economic Impact and Treatment Paradigm - There is a significant health economic burden in the hospital setting for treating acute exacerbations in asthma and COPD, with current standard care relying on β-agonist bronchodilators and systemic steroids [3] - Rademikibart's rapid bronchodilation could provide a new treatment option that directly addresses underlying inflammatory drivers [3][5] Group 5: Company Overview - Connect Biopharma is a clinical-stage biopharmaceutical company focused on transforming care for asthma and COPD, headquartered in San Diego, California [8] - The company is advancing rademikibart as a next-generation antibody targeting IL-4Rα, with significant unmet needs in the treatment of acute exacerbations [8]

Core Insights - Connect Biopharma Holdings Limited announced the presentation of Phase 3 study results for rademikibart in moderate-to-severe atopic dermatitis at the 2026 AAD Annual Meeting [1][2] - The CEO of Connect Biopharma expressed optimism regarding the study results, which may support the approval of Simcere's New Drug Application (NDA) for rademikibart in China [2] - Rademikibart is a monoclonal antibody targeting IL-4Rα, aimed at treating Th2-related inflammatory diseases [3] Company Overview - Connect Biopharma is a clinical-stage biopharmaceutical company focused on asthma and chronic obstructive pulmonary disease (COPD) [5] - The company is advancing rademikibart, which is designed to target IL-4Rα, and has granted an exclusive license to Simcere for its development in Greater China [5] - Connect Biopharma is eligible for milestone payments up to approximately $110 million and tiered royalties on net sales in Greater China [5] Partner Overview - Simcere Pharmaceutical Co., Ltd. is an innovation-driven pharmaceutical company founded in 1995, focusing on various therapeutic areas including neuroscience and autoimmune diseases [4] - Simcere has established strategic partnerships with multiple innovative biotechs and research institutes to enhance its R&D capabilities [4]

Core Insights - Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company focused on treating inflammatory diseases, particularly asthma and COPD [3] Company Participation - Company management will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on March 10, 2026, at 8:00 a.m. ET [1] Webcast Information - The live webcast of the presentation will be accessible via the Investors section of the Connect Biopharma website, with an archived replay available for approximately 90 days post-conference [2] Product Development - Connect Biopharma is advancing rademikibart, a next-generation antibody targeting IL-4Rα, currently undergoing global clinical studies for acute exacerbations of asthma and COPD [3] - The company has granted an exclusive license for rademikibart to Simcere Pharmaceutical Co., Ltd. in Greater China, with potential milestone payments up to approximately $110 million and tiered royalties on net sales [3]

Summary of Conference Call on Connect's Rademikibart Company Overview - **Company**: Connect - **Industry**: Biopharmaceuticals - **Focus**: Development of rademikibart, a next-generation monoclonal antibody targeting IL-4 RA for asthma and COPD treatment [1][2] Core Insights and Arguments - **Product Development**: Rademikibart has completed studies in atopic dermatitis and chronic asthma, with ongoing Phase III studies in China for both indications [2][3] - **Market Opportunity**: There is a significant global market for asthma and COPD, with approximately 40% of patients experiencing exacerbations annually, leading to millions of emergency visits [3][4] - **Unique Mechanism**: Rademikibart binds differently to IL-4 RA compared to existing treatments, resulting in a distinct clinical profile, including a decrease in eosinophil levels, which is beneficial for asthma patients [5][6][8] - **Rapid Onset of Action**: Clinical data indicates that rademikibart shows significant improvement in airway function within 24 hours, making it suitable for acute exacerbations [12][19] - **Comparison with Competitors**: Unlike Dupixent, which may increase eosinophil levels, rademikibart demonstrates a decrease, potentially reducing serious adverse events associated with eosinophilia [9][10][11] Additional Important Points - **Acute Treatment Studies**: Two studies are currently enrolling patients with acute exacerbations of asthma and COPD, with results expected mid-year [15][22] - **Market Research Findings**: There is a strong interest in rademikibart for acute treatment, with a projected peak sales opportunity of up to $5 billion for both acute and chronic indications [21][27] - **Regulatory Pathway**: The company is in discussions with the FDA regarding the Phase III program for acute treatment, which is expected to be shorter and less costly than traditional studies [28][29] - **Financial Position**: Connect has sufficient cash reserves to support operations until 2027, with significant milestones and royalties anticipated from partnerships [23][24] Conclusion Connect is positioned to capitalize on a substantial market opportunity with rademikibart, leveraging its unique mechanism of action and rapid onset of effect to address unmet needs in asthma and COPD treatment. The company is actively pursuing regulatory approvals and has a solid financial foundation to support its development efforts [22][23]

Company Overview - Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, particularly asthma and COPD [3] - The company is headquartered in San Diego, California and is advancing rademikibart, a next-generation antibody targeting IL-4Rα [3] Product Development - Connect Biopharma is conducting global clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD, which are areas with significant unmet medical needs [3] - The company has granted an exclusive license to Simcere Pharmaceutical Co., Ltd. for rademikibart in Greater China, with potential milestone payments up to approximately $110 million upon achieving certain development, regulatory, and commercial milestones [3] - Connect is also eligible to receive tiered royalties on net sales in Greater China, with rates up to low double-digit percentages [3] Upcoming Events - Company management will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, at 2:40 p.m. ET [1] - A live webcast of the presentation will be available on the company's investor website, with an archived replay accessible for approximately 90 days following the conference [2]

Group 1: Market Movements - Biotech and healthcare companies experienced notable movements in after-hours trading, with several small-cap firms showing strong gains due to corporate updates and investor momentum [1] Group 2: Company Updates - Plus Therapeutics, Inc. (PSTV) surged 8.40% to close at $0.31 after announcing a public offering priced at $0.38 per unit, aiming to raise approximately $15 million to support its precision diagnostics and radiopharmaceutical programs targeting central nervous system cancers [2] - Connect Biopharma Holdings Limited (CNTB) gained 5.96% to $2.31, recently highlighting new mechanism of action data for its lead candidate and outlining strategic priorities for 2026 [3] - ABVC BioPharma, Inc. (ABVC) added 3.37% to finish at $2.15, with the increase attributed to broader sector momentum rather than new corporate updates [3] - Modular Medical, Inc. (MODD) advanced 5.23% to $0.49, experiencing renewed buying interest despite no new news [4] - Traws Pharma, Inc. (TRAW) rose 2.82% to $1.82 after announcing the filing of a U.S. IND application for its potential oral therapy for influenza, supporting investor optimism around its pipeline [4] - Tiziana Life Sciences Ltd (TLSA) posted a 2.72% gain to $1.51 with no new developments reported [5] - Elutia Inc. (ELUT) climbed 6.64% to $0.90, following a corporate update outlining upcoming milestones for its next-generation antibiotic-eluting biomatrix program [5]

Core Insights - Connect Biopharma is advancing rademikibart, a monoclonal antibody targeting IL-4Rα, with promising data supporting its best-in-class potential for treating asthma and COPD [1][6][7] Development Highlights - New data demonstrates a unique mechanism of action for rademikibart, indicating its ability to rapidly improve airway function by reversing the negative effects of IL-4 and IL-13 [2][5] - Recruitment is ongoing for a Phase 1b study of intravenously-administered rademikibart, with topline results expected in the first quarter of 2026 [1][5] - The Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD are also ongoing, with topline data anticipated in mid-2026 [1][5] Financial Guidance - As of September 30, 2025, the company reported cash, cash equivalents, and short-term investments totaling $54.8 million, which are expected to fund operations into 2027 [4] Mechanism of Action - Rademikibart shows enhanced binding affinity to IL-4R, creating a more stable complex compared to dupilumab, leading to greater efficacy and safety [5] - In vitro studies indicate that rademikibart significantly improves responsiveness to β-agonist treatment in the presence of IL-4/IL-13, unlike dupilumab [5] Company Overview - Connect Biopharma is focused on transforming care for asthma and COPD, with rademikibart positioned as a next-generation treatment option [7] - The company has an exclusive licensing agreement with Simcere Pharmaceutical Co., Ltd. for rademikibart in Greater China, with potential milestone payments up to approximately $110 million [7]

Corporate Presentation for JPM January 2026 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended (the "Act"). Forward-looking statements are statements that are not of historical fact and include, without limitation, statements regarding future events, our future financial condition, results of operations, business strategy and plans, prospective products (as well as their potential to achiev ...